Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firsekibart in Acute Gouty Arthritis
NCT07625514Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2026
- Primary completion
- Aug 2029
- Countries
- 1
01
Overview
Open-label, single-arm trial of genakumab in gouty arthritis, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Proportion of patients experiencing at least one gout recurrence at 24 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
genakumab
03
Conditions
gouty arthritis
Beyond the preview
Go deeper on NCT07625514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07625514.